Related references
Note: Only part of the references are listed.Insulin glargine and receptor-mediated signalling: Clinical implications in treating type 2 diabetes
Derek Le Roith
DIABETES-METABOLISM RESEARCH AND REVIEWS (2007)
Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells
K. Staiger et al.
HORMONE AND METABOLIC RESEARCH (2007)
Insulin glulisine - A comprehensive preclinical evaluation
I Stammberger et al.
INTERNATIONAL JOURNAL OF TOXICOLOGY (2006)
A novel insulin analog with unique properties -: LysB3,GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1
I Rakatzi et al.
DIABETES (2003)
Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice
I Stammberger et al.
INTERNATIONAL JOURNAL OF TOXICOLOGY (2002)
Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects
J Dupont et al.
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY (2001)
Insulin and analogue effects on protein degradation in different cell types - Dissociation between binding and activity
J Fawcett et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use
P Kurtzhals et al.
DIABETES (2000)
Share Paper
